{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.8","upperLimit":"53.6","value":"40.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"}],"units":"Participants"}],"description":"Progression is defined according to RECIST v1.0 as at least a 20% increase in the sum of LD target lesions taking as reference the smallest sum LD recorded since study entry, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or unequivocal progression of existing non-target lesions.","dispersionType":"90% Confidence Interval","groups":[{"description":"Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy","id":"OG000","title":"Bevacizumab"}],"paramType":"NUMBER","populationDescription":"Eligible and treated patients.","reportingStatus":"POSTED","timeFrame":"Every other cycle for 6 months.","title":"Progression-free Survival at 6 Months","type":"PRIMARY","unitOfMeasure":"percentage of participants"}